SYMERES NETHERLANDS BV

Their core work

Symeres (formerly Mercachem) is a Dutch contract research organization specializing in medicinal chemistry and drug discovery services. They design and synthesize compound libraries for pharmaceutical screening, helping academic and industry partners identify promising drug candidates faster. Their capabilities span from hit-to-lead chemistry through pharmaceutical formulation, with particular strength in building diverse chemical libraries for high-throughput screening campaigns. They operate as a commercial partner embedded in research consortia, contributing hands-on chemistry expertise rather than theoretical research.

What they specialise in

How they've shifted over time

All three H2020 projects started in 2018, making it difficult to identify a strong temporal shift in focus. However, the portfolio reveals a dual strategy: broad drug discovery infrastructure (iDESIGN, ESCulab) alongside a targeted therapeutic application in ophthalmology (IT-DED3). The move into dry eye disease drug development suggests Symeres was beginning to apply its general chemistry capabilities to specific disease areas rather than only providing platform services.

Symeres appears to be shifting from pure chemistry service provision toward deeper integration in disease-specific drug development pipelines, which could make them a more strategic partner for therapeutic-focused consortia.

How they like to work

Symeres has never coordinated an H2020 project — they join as a specialist partner or third party, contributing chemistry expertise to larger consortia. With 38 unique partners across 11 countries from just 3 projects, they operate in large, multi-national training and research networks (MSCA-ITN format). This profile suggests a company that is easy to integrate into consortia as a reliable industry partner providing concrete deliverables rather than project management.

Despite only 3 projects, Symeres has collaborated with 38 unique partners across 11 countries, reflecting the large consortium sizes typical of Marie Curie training networks. Their network is broadly European with no single dominant geographic cluster.

What sets them apart

Symeres fills a specific gap in EU research consortia: they are a commercial medicinal chemistry company that can translate academic biological discoveries into actual drug-like compounds and screening-ready libraries. Unlike university labs that do exploratory chemistry, Symeres brings industrial-scale synthesis and compound quality standards. For consortium builders, they represent a credible industry partner with both the infrastructure and the willingness to participate in publicly funded training and research programs.

Highlights from their portfolio

• iDESIGN
  Largest funding (EUR 624K) — focused on AI-driven compound library design, combining computational and synthetic chemistry at scale.
• ESCulab
  Part of the European Screening Centre initiative, a continental-scale effort to build shared screening libraries for drug discovery.
• IT-DED3
  Integrated training network covering the full dry eye drug pipeline from biology through formulation — shows Symeres engaging beyond pure chemistry into therapeutic applications.